All Diagnostic Kits

Maxim HIV-1 Urine Enzyme Immunoassay (EIA) Kit, 480 Tests

Maxim's FDA Approved HIV-1 Urine EIA test is an enzyme immunoassay for the in-vitro detection of antibodies to Human Immunodeficiency Virus Type 1 (HIV-1) in urine. The test is intended for use in professional laboratory settings as an aid in clinical diagnosis of HIV infection. Before a determination of HIV-1 status can be made, specimens that are repeatedly reactive using this test should be further tested using Maxim's additional, more specific FDA approved Cambridge Biotech Western Blot Kit.

Application:

Target:

HIV-1

ELISA

Sample Type:

Urine

Maxim HIV-1 Limiting Antigen Avidity (LAg-Avidity) EIA Kit, 192 Tests

The Maxim HIV-1 Limiting Antigen-Avidity EIA is an in-vitro quantitative limiting antigen (LAg) avidity enzyme immunoassay for distinguishing recent HIV-1 infections from those which are long-term. Persons with recently acquired HIV-1 infections typically exhibit HIV-1 specific IgG populations with higher proportions of lower avidity IgG than those with long-term infections which typically exhibit higher proportions of higher avidity IgG. The Maxim HIV-1 LAg-Avidity EIA uses US CDC developed technology and is designed for surveillance purposes such as estimating HIV-1 incidence in a population, monitoring and evaluating HIV intervention programs, and recognizing those high-incidence populations so that prevention research, vaccine trials, and resources are most appropriately utilized. This product is for research use only and is not intended for use in diagnostic procedures.

Application:

Target:

HIV-1

ELISA

Sample Type:

Serum/Plasma

Maxim Swift™ HIV Recent Infection Assay (RIA) Kit, 20 Tests

The Maxim Swift™ HIV Recent Infection Assay (RIA) is a single use qualitative immunoassay to detect the circulating antibodies to Human Immunodeficiency Virus Type 1 (HIV-1), Type 2 (HIV-2) and distinguish between recent and long-term infection in HIV-1/2. The assay is a point of care (POC) test intended for use with blood or serum/ plasma specimens. The Maxim Swift™ HIV RIA uses US CDC developed materials and is designed for surveillance purposes such as estimating HIV-1 incidence in a population, monitoring and evaluating HIV intervention programs, and recognizing those high-incidence populations so that prevention research, vaccine trials, and resources are most appropriately utilized. This product is for research use only and is not intended for use in diagnostic procedures. This product is for research purposes only.

Application:

Target:

HIV-1

LFI

Sample Type:

Serum/Plasma & Whole Blood

Maxim Swift™ HIV Recent Infection Assay (RIA) Controls Kit

The Maxim Swift™ HIV Recent Infection Assay (RIA) Kit Controls are quality control reagents for use only with the Maxim Swift™ HIV Recent Infection Assay (RIA) (P/N 92002). They are used to verify that the test kit reagents are working and that the test is performed correctly. The Maxim Swift™ HIV RIA uses US CDC developed materials and is designed for surveillance purposes such as estimating HIV-1 incidence in a population, monitoring and evaluating HIV intervention programs, and recognizing those high-incidence populations so that prevention research, vaccine trials, and resources are most appropriately utilized. Controls should be stored at 4-8°C for long-term storage (12 months) or at -20°C (24 months). This product is for research use only and is not intended for use in diagnostic procedures.

Application:

Target:

HIV-1

LFI

Sample Type:

Serum/Plasma

Maxim HIV-1 Limiting Antigen Avidity (LAg-Avidity) DBS EIA Kit, 192 Tests

The Maxim HIV-1 Limiting Antigen-Avidity Dried Blood Spot (DBS) EIA is an in-vitro quantitative limiting antigen (LAg) avidity enzyme immunoassay for distinguishing recent HIV-1 infections from those which are long-term. Persons with recently acquired HIV-1 infections typically exhibit HIV-1 specific IgG populations with higher proportions of lower avidity IgG than those with long-term infections which typically exhibit higher proportions of higher avidity IgG. The Maxim HIV-1 LAg-Avidity DBS EIA uses US CDC developed technology and is designed for surveillance purposes such as estimating HIV-1 incidence in a population, monitoring and evaluating HIV intervention programs, and recognizing those high-incidence populations so that prevention research, vaccine trials, and resources are most appropriately utilized. This product is for research use only and is not intended for use in diagnostic procedures.

Application:

Target:

HIV-1

ELISA

Sample Type:

Dried Blood Spot (DBS)

Cambridge Biotech HIV-1 Serum Western Blot, 27 Tests

Maxim's Cambridge biotech HIV-1 Serum Western Blot Kit is an FDA Approved in-vitro qualitative assay for the detection and identification of antibodies to Human Immunodeficiency Virus Type 1 (HIV-1) contained in human serum or plasma. It is intended for use with persons of unknown risks as an additional specific test on human serum or plasma specimens found to be repeatedly reactive using a screening procedure, such as an Enzyme-Linked Immunosorbent Assay (ELISA).

Application:

Target:

HIV-1

WB

Sample Type:

Serum/Plasma

Cambridge Biotech HIV-1 Urine Western Blot, 27 Tests

Maxim's Cambridge Biotech HIV-1 Urine Western Blot Kit is an FDA approved in-vitro qualitative assay for the detection and identification of antibodies to Human Immunodeficiency Virus Type 1 (HIV-1) contained in human urine. This more specific assay is used as a supplemental test with urine specimens that tested repeatedly reactive using a screening procedure (e.g. FDA Approved Maxim HIV-1 Urine EIA).

Application:

Target:

HIV-1

WB

Sample Type:

Urine

Ready to Order?

Contact us to get a quote now!

arrow&v

Contact

Maxim Biomedical, Inc.

1500 East Gude Drive, Rockville, MD 20850

Tel: 301-251-0800

Fax: 301-762-1542

E-mail: info@mbidiagnostic.com

Products

© 2019 Maxim Biomedical, Inc.